CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.03BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.2520xvs all stocks
52-Week Change
46.16%vs all stocks
Market Capitalization
1.03BUSDvs all stocks (USD)
Enterprise Value
1.13BUSDvs all stocks (USD)
Forward P/E
-16.03xvs Biotechnology peers
Price to Book (MRQ)
8.85xvs Biotechnology peers
Enterprise to EBITDA
-7.89xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-50.14%vs Biotechnology peers
Return on Equity (TTM)
-105.48%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
-86.84MUSDvs all stocks (USD)
EBITDA (TTM)
-142.70MUSDvs all stocks (USD)
Net Income (TTM)
-139.31MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-110.38MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-57.19MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-122.76MUSDvs all stocks (USD)
Pre-tax Income
-118.84MUSDFY2025 · Dec 31, 2025Net Income
-118.84MUSDFY2025 · Dec 31, 2025EBIT
-122.76MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-122.44MUSDFY2025 · Dec 31, 2025Research & Development
81.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
42.06MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.16MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5300USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5300USDFY2025 · Dec 31, 2025Basic Shares Outstanding
222.39MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
222.39MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-118.84MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-98.97MUSDFY2025 · Dec 31, 2025Free Cash Flow
-98.99MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
33.18MUSDFY2025 · Dec 31, 2025Interest Paid
3.20MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-118.84MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
87.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.42MUSDFY2025 · Dec 31, 2025Other Non-cash Items
453.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.81MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
98.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-22.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-204.90MUSDFY2025 · Dec 31, 2025Sale of Investments
186.48MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-18.44MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
29.60MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-27.23MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-5.14MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
137.46MUSDFY2025 · Dec 31, 2025Shares Outstanding
205.40MSharesUpdated Sep 28, 2026Float Shares
129.80MSharesUpdated Sep 28, 2026Shares Short
43.34MSharesUpdated Sep 28, 2026Short Ratio
29.34daysvs all stocks
Short % of Shares Outstanding
24.66%vs all stocks
% Held by Insiders
2.59%vs all stocks
% Held by Institutions
106.75%vs all stocks
Total Cash (MRQ)
174.82MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6880USDUpdated Sep 28, 2026Total Debt (MRQ)
30.41MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2117xvs Biotechnology peers
Current Ratio (MRQ)
10.13xvs Biotechnology peers
Book Value per Share (MRQ)
0.5650USDUpdated Sep 28, 2026Total Assets
253.44MUSDvs all stocks (USD)
Total Current Assets
241.62MUSDFY2025 · Dec 31, 2025Total Liabilities
50.30MUSDFY2025 · Dec 31, 2025Total Non-current Assets
11.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
29.91MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.40MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
33.18MUSDFY2025 · Dec 31, 2025Other Short-term Investments
202.52MUSDFY2025 · Dec 31, 2025Accounts Payable
5.76MUSDFY2025 · Dec 31, 2025Short-term Debt
7.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
362.00KUSDFY2025 · Dec 31, 2025Long-term Debt
29.91MUSDFY2025 · Dec 31, 2025Common Stock (Book)
204.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-608.09MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
203.13MUSDvs all stocks (USD)
52-Week Low
3.34USDUpdated Sep 28, 202652-Week High
7.00USDUpdated Sep 28, 202652-Week Change
46.16%vs all stocks
Beta
0.2520xvs all stocks
50-Day MA
5.44USDUpdated Sep 28, 2026200-Day MA
5.57USDUpdated Sep 28, 2026Avg 10-Day Volume
1.82MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.61MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.5800USDUpdated Sep 28, 2026Other Income / Expense
-236.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Altman Z-Score 8.34: safe zoneNotable
Altman Z-Score: 8.34
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MoonLake Immunotherapeutics
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Animal Husbandry Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangyuyuan Chinese Herbal Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule